Medpace Holdings Valuation
Is MEDP * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MEDP * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEDP * (MX$7176) is trading below our estimate of fair value (MX$11287.81)
Significantly Below Fair Value: MEDP * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEDP *?
Key metric: As MEDP * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MEDP *'s PE Ratio? | |
|---|---|
| PE Ratio | 28.7x |
| Earnings | US$365.57m |
| Market Cap | US$10.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.8x |
| Enterprise Value/EBITDA | 22.8x |
| PEG Ratio | 2.6x |
Price to Earnings Ratio vs Peers
How does MEDP *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 37.2x | ||
2269 WuXi Biologics (Cayman) | 20.9x | 17.9% | HK$59.2b |
CRL Charles River Laboratories International | 24.2x | 11.7% | US$10.0b |
BRKR Bruker | 28.4x | 32.3% | US$8.7b |
TECH Bio-Techne | 75.2x | 21.2% | US$11.3b |
MEDP * Medpace Holdings | 28.7x | 10.9% | Mex$10.5b |
Price-To-Earnings vs Peers: MEDP * is good value based on its Price-To-Earnings Ratio (28.7x) compared to the peer average (37.2x).
Price to Earnings Ratio vs Industry
How does MEDP *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: MEDP * is good value based on its Price-To-Earnings Ratio (28.7x) compared to the Global Life Sciences industry average (35.6x).
Price to Earnings Ratio vs Fair Ratio
What is MEDP *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 28.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEDP *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$6,925.05 0% | 9.7% | Mex$8,008.98 | Mex$5,867.96 | n/a | 10 |
| Nov ’25 | n/a | Mex$6,925.57 0% | 9.7% | Mex$8,009.58 | Mex$5,868.41 | n/a | 10 |
| Oct ’25 | n/a | Mex$7,489.34 0% | 12.7% | Mex$8,570.54 | Mex$5,831.91 | n/a | 10 |
| Sep ’25 | Mex$6,890.00 | Mex$7,430.43 +7.8% | 12.1% | Mex$8,165.86 | Mex$5,556.54 | n/a | 10 |
| Aug ’25 | n/a | Mex$7,430.43 0% | 12.1% | Mex$8,165.86 | Mex$5,556.54 | n/a | 10 |
| Jul ’25 | n/a | Mex$7,921.41 0% | 12.1% | Mex$8,862.38 | Mex$5,465.14 | n/a | 9 |
| Jun ’25 | n/a | Mex$7,261.88 0% | 12.9% | Mex$8,139.41 | Mex$5,019.30 | n/a | 8 |
| May ’25 | n/a | Mex$7,264.54 0% | 13.7% | Mex$8,195.57 | Mex$5,053.93 | n/a | 7 |
| Apr ’25 | n/a | Mex$6,556.53 0% | 18.6% | Mex$8,079.94 | Mex$4,393.47 | n/a | 6 |
| Mar ’25 | n/a | Mex$6,525.40 0% | 19.2% | Mex$7,722.06 | Mex$4,449.14 | n/a | 5 |
| Feb ’25 | n/a | Mex$4,875.49 0% | 8.9% | Mex$5,371.30 | Mex$4,114.55 | n/a | 5 |
| Jan ’25 | n/a | Mex$4,911.97 0% | 8.2% | Mex$5,275.31 | Mex$4,174.83 | n/a | 5 |
| Dec ’24 | n/a | Mex$5,104.17 0% | 7.6% | Mex$5,532.88 | Mex$4,378.67 | n/a | 5 |
| Nov ’24 | n/a | Mex$5,104.17 0% | 7.6% | Mex$5,532.88 | Mex$4,378.67 | n/a | 5 |
| Oct ’24 | n/a | Mex$4,361.74 0% | 6.4% | Mex$4,597.51 | Mex$3,822.84 | n/a | 5 |
| Sep ’24 | n/a | Mex$4,361.74 0% | 6.4% | Mex$4,597.51 | Mex$3,822.84 | Mex$6,890.00 | 5 |
| Aug ’24 | n/a | Mex$4,361.74 0% | 6.4% | Mex$4,597.51 | Mex$3,822.84 | n/a | 5 |
| Jul ’24 | n/a | Mex$3,841.08 0% | 6.3% | Mex$4,298.19 | Mex$3,667.10 | n/a | 5 |
| Jun ’24 | n/a | Mex$4,001.16 0% | 7.0% | Mex$4,486.28 | Mex$3,827.58 | n/a | 4 |
| May ’24 | Mex$3,780.00 | Mex$3,913.38 +3.5% | 0.4% | Mex$3,937.57 | Mex$3,901.28 | n/a | 3 |
| Apr ’24 | n/a | Mex$4,135.48 0% | 7.3% | Mex$4,514.88 | Mex$3,775.05 | n/a | 3 |
| Mar ’24 | n/a | Mex$4,261.43 0% | 3.9% | Mex$4,422.47 | Mex$4,032.25 | n/a | 3 |
| Feb ’24 | Mex$4,250.00 | Mex$4,268.33 +0.4% | 3.8% | Mex$4,475.16 | Mex$4,080.29 | n/a | 3 |
| Jan ’24 | Mex$4,168.00 | Mex$4,335.62 +4.0% | 7.1% | Mex$4,726.16 | Mex$3,971.56 | n/a | 3 |
| Dec ’23 | Mex$4,115.00 | Mex$4,216.76 +2.5% | 7.1% | Mex$4,596.59 | Mex$3,862.68 | n/a | 3 |
| Nov ’23 | Mex$4,394.82 | Mex$4,331.36 -1.4% | 7.1% | Mex$4,721.52 | Mex$3,967.66 | n/a | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a